Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation

(2019) Malgorzata Krajewska et al.   Nature Communications

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

(2018) Amanda Balboni Iniguez et al.   CANCER CELL

SUMO suppresses and MYC amplifies transcription globally by regulating CDK9 sumoylation

(2018) Fang Yu et al.   CELL RESEARCH

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence

(2018) James J Morrow et al.   NATURE MEDICINE

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

(2018) Sara J. Dubbury et al.   NATURE

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

(2018) Kendall R. Sanson et al.   Nature Communications

HCMDB: the human cancer metastasis database

(2017) Guantao Zheng et al.   NUCLEIC ACIDS RESEARCH

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

(2017) Sam Behjati et al.   Nature Communications

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

(2016) Neyssa M Marina et al.   LANCET ONCOLOGY

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

(2016) Tinghu Zhang et al.   Nature Chemical Biology

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop

(2016) Pooja Hingorani et al.   Cancer Genetics

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

(2015) A. Gupte et al.   CLINICAL CANCER RESEARCH

Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing

(2015) Kaiwei Liang et al.   MOLECULAR AND CELLULAR BIOLOGY

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

(2015) Branden S Moriarity et al.   NATURE GENETICS

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells

(2015) Ling Ren et al.   Oncotarget

Genomic Instability of Osteosarcoma Cell Lines in Culture: Impact on the Prediction of Metastasis Relevant Genes

(2015) Roman Muff et al.   PLoS One

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex

(2014) Bartlomiej Bartkowiak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

(2014) Poorval M. Joshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

(2014) Nicholas Kwiatkowski et al.   NATURE

Outcome for Children with Metastatic Solid Tumors over the Last Four Decades

(2014) Stephanie M. Perkins et al.   PLoS One

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

(2014) Jennifer A. Perry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

(2013) Edward Y Chen et al.   BMC BIOINFORMATICS

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

(2012) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells

(2011) A. Natoni et al.   MOLECULAR CANCER THERAPEUTICS

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

(2010) B. Bartkowiak et al.   GENES & DEVELOPMENT

Modeling metastasis biology and therapy in real time in the mouse lung

(2010) Arnulfo Mendoza et al.   JOURNAL OF CLINICAL INVESTIGATION

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma

(2010) Michiro Susa et al.   PLoS One

Osteosarcoma incidence and survival rates from 1973 to 2004

(2009) Lisa Mirabello et al.   CANCER

The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity

(2009) S. Ali et al.   CANCER RESEARCH

Establishment and characterization of a new highly metastatic human osteosarcoma cell line

(2009) Yuxi Su et al.   CLINICAL & EXPERIMENTAL METASTASIS

ChIP-seq: Using high-throughput sequencing to discover protein–DNA interactions

(2009) Dominic Schmidt et al.   METHODS

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

(2009) K. F. Byth et al.   MOLECULAR CANCER THERAPEUTICS

Progression through the RNA Polymerase II CTD Cycle

(2009) Stephen Buratowski   MOLECULAR CELL